PMCB
PharmaCyte Biotech, Inc.NASDAQHealthcare$0.69+0.10%ClosedMarket Cap: $4.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.17
P/S
0.00
EV/EBITDA
1.19
DCF Value
$2.49
FCF Yield
-99.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-7.7%
ROA
-5.9%
ROIC
-9.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2026 | $0.00 | NaN% | $-2.1M | $746.9K | $-0.17 | — |
| Q2 2026 | $0.00 | NaN% | $-1.4M | $-7.4M | $-1.24 | — |
| Q1 2026 | $0.00 | NaN% | $-848.3K | $-8.4M | $-1.23 | — |
| Q4 2025 | $0.00 | NaN% | $-1.0M | $11.7M | $1.60 | — |
| FY 2025 | $0.00 | NaN% | $-4.4M | $30.7M | $3.19 | — |
| Q3 2025 | $0.00 | NaN% | $-960.0K | $-3.0M | $-0.44 | — |
| Q2 2025 | $0.00 | NaN% | $-1.1M | $-1.5M | $-0.39 | — |
| Q1 2025 | $0.00 | NaN% | $-1.3M | $23.4M | $1.90 | — |
| Q4 2024 | $0.00 | NaN% | $-3.2M | $1.3M | $-0.30 | — |
| FY 2024 | $0.00 | NaN% | $-6.5M | $333.8K | $-1.80 | — |
| Q3 2024 | $0.00 | NaN% | $-1.9M | $-620.0K | $-0.65 | — |
| Q2 2024 | $0.00 | NaN% | $-1.4M | $2.8M | $-0.26 | — |